YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com - U.S. stock futures pointed lower on Wednesday ahead of the release of key minutes from the Federal Reserve's latest policy gathering, as investors looked for clues on the central bank's interest-rate outlook. Before you buy…
The death of a Russian lab technician triggers fears of a pneumonic plague outbreak, even as health officials downplay the risk. Continue Reading
Novavax stock (NVAX) fell on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a "low" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last w…
Good morning. Stock extended gains after the Nasdaq Composite (^IXIC) posted a fresh record, boosted by all-time highs in Nvidia (NVDA) shares. The S&P 500 also climbed within striking distance of its own record as Treasury yields eased. T…
Novavax NVAX shares soared 20.1% in the last trading session to close at $12.56. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% gain over the past four we…
3 Overrated Stocks We Approach with Caution The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financ…
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this vaccine maker have returned +14.8% o…
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q2. Today, we are lookin…
3 Volatile Stocks with Questionable Fundamentals Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most exper…
Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer…
[A cardboard sign with the diagnosis of autism made of multicolored letters in the hands of a child on a purple background with pieces of colorful puzzles.] Maryna Auramchuk/iStock via Getty Images * HHS is expected to unveil an autism res…
Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same…
Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act,…
Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Mo…
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this vaccine maker h…
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader…
3 Russell 2000 Stocks We're Skeptical Of The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher v…
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Over t…
3 of Wall Street's Favorite Stocks with Open Questions Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it's important to remain skeptical because analysts face in…
Company Logo Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Ti…
[Covid-19 vaccine in a vial, immunization and treatment of infection] Kittisak Kaewchalun An Army doctor is working with Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth to investigate whether U.S. troops died from…
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lat…
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, New York Fires…
Quick Read NVAX jumped 7% on unverified Matrix-M oncology speculation, even as the real story had already quietly resumed: high-teens royalties on Sanofi's Nuvaxovid global net sales restarted for 2026 and 2027. IBB gained just 0.2% while…
Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major…
Novavax (NVAX) drew fresh attention after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS CoV 2 XFG variant for the 2026 to 2027 vaccination season. The news has arrived after a mixed peri…
This article first appeared on GuruFocus. Pfizer (NYSE:PFE), the global pharmaceutical and vaccine heavyweight, won FDA approval Thursday for its XFG-adapted Comirnaty vaccine, giving shares priced at $27.9079 on August 28 a fresh catalyst…
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, provi…
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs. Today's drop has put the equity in a deficit for the quarter, though NVAX shares remain 36% higher y…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Wall Street’s major averages closed firmly higher on Friday, with Treasury yields largely steady and Bitcoin experiencing sharp intraday swings. The Dow Jones Industrial Average advanced 0.9%, the S&P 500 rose 0.4%, and the Nasdaq Composit…
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical Check out the companies making headlines this week: Bally's (NYSE:BALY): Gaming, betting and entertainment company Bally's Corporation (NYSE:BALY) rose…
[US Department of Health and Human Services] * HHS has issued a formal Request for Information that seeks public input on the categories used in federal vaccine recommendations and how shared decision-making between patients and doctors fi…
Biotech research by Gorodenkoff via Shutterstock Novavax (NVAX) is a biotechnology company headquartered in Gaithersburg, Maryland, focused on the discovery, development, and commercialization of vaccines that address serious infectious di…
The stock jumps after a melanoma treatment has success in a late-stage trial. One analyst says annual sales could hit $3 billion by 2035. Continue Reading
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the…